Premature senescence induced by DNA demethylating agent (Decitabine) as therapeutic option for malignant pleural mesothelioma

Lung Cancer

Volumn 71, Issue 1, 2011, Pages 113-115

  Amatori, S ^a   Bagaloni, I ^a   Viti, D ^a   Fanelli, M ^a  

^a UNIVERSITY OF URBINO   (Italy)

Author keywords

Decitabine; DNA demethylation; Drug induced premature senescence; Malignant pleural mesothelioma

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ATM PROTEIN; ATR PROTEIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; HISTONE H2AX; PROTEIN P16; PROTEIN P21; PROTEIN P27;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CELL AGING; CONCENTRATION RESPONSE; DNA METHYLATION; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION; HUMAN; IN VITRO STUDY; LETTER; MALIGNANT MESOTHELIOMA; MALIGNANT PLEURA MESOTHELIOMA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR SUPPRESSOR GENE;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CELL AGING; DNA METHYLATION; HUMANS; MESOTHELIOMA; PLEURAL NEOPLASMS;

EID: 78650201751     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.10.016     Document Type: Letter

References (11)

1. Weiner S.J., Neragi-Miandoab S. Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors. Cancer Res Clin Oncol 2009, 135:15-27.
2. Amatori S., Papalini F., Lazzarini R., Donati B., Bagaloni I., Rippo M.R., et al. Decitabine, differently from DNMT1 silencing, exerts its antiproliferative activity through p21 upregulation in malignant pleural mesothelioma (MPM) cells. Lung Cancer 2009, 66:184-190.
3. Collado M., Blasco M.A., Serrano M. Cellular senescence in cancer and aging. Cell 2007, 130:223-233.
4. Schrump D.S., Fischette M.R., Nguyen D.M., Zhao M., Li X., Kunst T.F., et al. Phase I study of Decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 2006, 12:5777-5785.
5. Young J.I., Smith J.R. DNA methyltransferase inhibition in normal human fibroblasts induces a p21-dependent cell cycle withdrawal. J Biol Chem 2001, 276(22):19610-19616.
6. Amatori S., Bagaloni I., Donati B., Fanelli M. DNA demethylating antineoplastic strategies: a comparative point of view. Genes Cancer 2010, 1(3):197-209.
7. Amatori S., Bagaloni I., Macedi E., Formica M., Giorgi L., Fusi V., et al. Malten, a new synthetic molecule showing in vitro antiproliferative activity against tumor cells and induction of complex DNA structural alterations. Br J Cancer 2010, 103:239-248.
8. Gewirtz D.A., Holt S.E., Elmore L.W. Accelerated senescence: an emerging role in tumor cell response to chemotherapy and radiation. Biochem Pharmacol 2008, 76:947-957.
9. Tront J.S., Hoffman B., Liebermann D.A. Gadd45a suppresses Ras-driven mammary tumorigenesis by activation of c-Jun NH2-terminal kinase and p38 stress signaling resulting in apoptosis and senescence. Cancer Res 2006, 66:8448-8454.
10. Narita M., Nunez S., Heard E., Narita M., Lin A.W., Hearn S.A., et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 2003, 113:703-713.
11. Soriani A., Zingoni A., Cerboni C., Iannitto M.L., Ricciardi M.R., Di Gialleonardo V., et al. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 2009, 113(15):3503-3511.